|
|
 |
Call
Oveda Slade at
919-403-6583 to ask questions and learn more about managed markets
departmental structure and reimbursement strategy.
|
Managed Markets:
Pharmaceutical Reimbursement Strategy, Organizational Structure and
Medicare Part D (PH77)
|

5th Annual
Formulary & Reimbursement Strategies for Effective Product Planning

September 25-26, 2008
Philadelphia, PA
Register Now!
|
Benchmark your managed markets department's size and structure
against those of top-tier firms, mid-size companies, and small
pharmas and biotechs. Identify the structural differences and
strategic business drivers that differentiate companies in each of
these groups, and learn about the pitfalls that commonly affect
managed markets departments at each level. Use product-specific
headcounts and budgets to lobby for additional resources, and
prepare your company's strategy for incorporating the Medicare Part
D prescription drug benefit into structural changes, marketing
planning and account management realignments.
Managed Markets: Pharmaceutical Reimbursement Strategy,
Organizational Structure and Medicare Part D is a cutting-edge guide
for companies of all sizes:
- Top-tier companies' managed markets organizations use this
report to compare their account management forces, marketing
resources and support staff against the competition; justify
headcounts and budgets; and learn the latest strategies, structures,
processes and tactics for winning in the changing Medicare Part D
arena. The report analyzes the key business drivers, including pharmacoeconomic data collection, span and level of control over
insured lives integrated marketing and account management, and
account alignment, that differentiate the top-tier company managed
care operating environment from that of smaller firms.
- Mid-size companies use this report to identify the
organizational structures and headcounts they need as they expand
along the mid-tier spectrum from small operations to those
approaching top-tier status. The report's brand-specific budgets and
staffing data help ensure that their resource allocations are right
on the mark. Strategic insights help these companies develop a
detailed understanding of how Part D will affect their products.
- Small pharmaceutical and biotechnology companies can derive
many benefits from this report in a number of areas. Case studies of
other small companies' and mid-size and top-tier companies' managed
markets organizations present a roadmap for organizational growth
from having a few or even no dedicated resources to establishing a
small department of five or 10, to a mid-size organization of 20 or
60 FTEs, to a top-tier group of 100 or more managed markets staff.
Analysis of key business drivers at the various levels help small
companies identify the important clinical, health economics and
managed care activities they need to focus on as they grow.
|
More Cutting Edge
Information Reports: |
|
 |
 |
 |
|
|
|
|